CRISPR Therapeutics AG (NASDAQ: CRSP) on Friday, plunged -3.88% from the previous trading day, before settling in for the closing price of $41.29. Within the past 52 weeks, CRSP’s price has moved between $38.20 and $91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 39460.20%. The company achieved an average annual earnings per share of -167.04%. With a float of $81.68 million, this company’s outstanding shares have now reached $85.34 million.
Let’s determine the extent of company efficiency that accounts for 407 employees. In terms of profitability, gross margin is 30.6%, operating margin of -164.86%, and the pretax margin is -117.29%.
CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 4.30%, while institutional ownership is 69.50%. The most recent insider transaction that took place on Dec 02 ’24, was worth 826,564. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $55.10, taking the stock ownership to the 181,540 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Chief Executive Officer sold 30,000 for $55.62, making the entire transaction worth $1,668,678. This insider now owns 196,540 shares in total.
CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -167.04% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 21.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -1.22 in the next quarter and is forecasted to reach -4.99 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Looking closely at CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days average volume was 1.76 million, which is a jump from its year-to-date volume of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 42.05%. Additionally, its Average True Range was 2.10.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 7.14%, which indicates a significant decrease from 24.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.98% in the past 14 days, which was lower than the 49.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.61, while its 200-day Moving Average is $51.85. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $40.54. Second resistance stands at $41.38. The third major resistance level sits at $42.40. If the price goes on to break the first support level at $38.68, it is likely to go to the next support level at $37.66. Now, if the price goes above the second support level, the third support stands at $36.82.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
Market capitalization of the company is 3.39 billion based on 85,353K outstanding shares. Right now, sales total 371,210 K and income totals -153,610 K. The company made 600 K in profit during its latest quarter, and -85,940 K in sales during its previous quarter.
